Edesa Biotech, Inc. last reported quarterly results on Aug 13, 2026, for Q3 FY2026 (the quarter ended Jun 30, 2026). It usually reports 44–73 days after a quarter ends. Based on that pattern, the next release is estimated for around Dec 11, 2026.
Results for Q4 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on last year's release for the same quarter on Dec 12, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–73 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q3 FY2026
ended Jun 30, 2026
|
—
|
-5
-209.1%
|
—
|
|
May 14, 2026
44 days after quarter end
|
Q2 FY2026
ended Mar 31, 2026
|
—
|
-4
-165.2%
|
—
|
|
Feb 13, 2026
44 days after quarter end
|
Q1 FY2026
ended Dec 31, 2025
|
—
|
-2
-39.0%
|
—
|
|
Dec 12, 2025
73 days after quarter end
|
Q4 FY2025
ended Sep 30, 2025
|
—
|
-2
-131.6%
|
—
|
|
Aug 8, 2025
39 days after quarter end
|
Q3 FY2025
ended Jun 30, 2025
|
—
|
-2
-4.9%
|
—
|
|
May 14, 2025
44 days after quarter end
|
Q2 FY2025
ended Mar 31, 2025
|
—
|
-2
+14.6%
|
—
|
|
Feb 14, 2025
45 days after quarter end
|
Q1 FY2025
ended Dec 31, 2024
|
—
|
-2
+3.6%
|
—
|
|
Dec 13, 2024
74 days after quarter end
|
Q4 FY2024
ended Sep 30, 2024
|
—
|
-1
+44.1%
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EDSA (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Toronto
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1540159
- Former names
- Stellar Biotechnologies, Inc. (until May 30, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.